Trial · NCT03985943
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 24.6 | percentage of participants | ||
| Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 35.6 | percentage of participants | ||
| Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 21.4 | percentage of participants | ||
| Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 35.5 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 29.0 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 43.5 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 23.8 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 41.6 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 17.8 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 42.7 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 18.6 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 46.1 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 11.2 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 30.6 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 7.6 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 27.8 | percentage of participants | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 19.9 | percentage of subjects | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 37.9 | percentage of subjects | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 22.4 | percentage of participants | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 42.1 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03985943/results